A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.

Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

Precision medicine in prostate cancer utilizes genetic testing to identify patients for PARP inhibitor treatment, enhancing personalized care. Genetic testing, including germline and somatic, is ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Prostate Cancer is the second leading cause of death in American men after lung cancer. In 2018, 165,000 men will be diagnosed with prostate cancer. The question all men with prostate cancer need ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...